Opinion: Eli Lilly Stock Is a No-Brainer Pick to Buy on the Dip
This stock is worth loading up on whenever it's on the cheap side.
Overview
There's no rule that says a leading pharma stock can't go down. On that note, shares of Eli Lilly (NYSE: LLY) are still down by 7% from their recent high set in mid-August, even though its moneymaker metabolic medicines had powered 48% revenue growth in the second quarter.
Some investors seem to be afraid that the company's willingness to sell those drugs at competitive prices will erode its margins. But I think that fear is very much overblown and that this stock is obviously worth buying while it's marginally cheaper than before.
Image source: The Motley Fool.
Details
Source
Originally published at www.fool.com.
Related Articles
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.